Fudan University

🇨🇳China

Country: 🇨🇳China

Ownership: Private

Established: 1905-01-01

Employees: 1K

Market Cap: -

Website: http://www.fudan.edu.cn

Clinical Trials

Evaluation of Correlations Between Radiologic Features and Pathologic Subtypes of GGO LUAD Via WMS (ECTOP-1011)

Completed

Conditions: Adenocarcinoma of Lung

First Posted Date: 2022-02-23

Last Posted Date: 2023-07-21

Lead Sponsor: Fudan University

Target Recruit Count: 103

Registration Number: NCT05252676

Locations: 🇨🇳
Fudan University Cancer Center, Shanghai, Shanghai, China

Gonadotropin-releasing Hormone Agonist (GnRHa) Plus Letrozole In Young Women With Early Endometrial Cancer

Phase 2

Recruiting

Conditions: Endometrial Neoplasm Malignant Stage I

Interventions: Drug: Megestrol Acetate 160 MG Oral Tablet
Drug: Triprorelin Acetate
Drug: Medroxyprogesterone Acetate 500 MG
Drug: Letrozole 2.5mg

First Posted Date: 2022-02-18

Last Posted Date: 2025-04-06

Lead Sponsor: Fudan University

Target Recruit Count: 104

Registration Number: NCT05247268

Locations: 🇨🇳
Obstetrics and Gynecology Hospital, Fudan University, Shanghai, China

Parsaclisib in Combination With CHOP in Participants With Previously Untreated PTCL

Phase 1

Not yet recruiting

Conditions: CHOP
Parsaclisib
PI3Kδ Inhibitor
PTCL

Interventions: Drug: Parsaclisib
Drug: CHOP

First Posted Date: 2022-02-14

Last Posted Date: 2022-02-14

Lead Sponsor: Fudan University

Target Recruit Count: 30

Registration Number: NCT05238064

Irinotecan Plus Anlotinib or Further in Combination With Penpulimab for Second-line Treatment of mCRC

Phase 2

Recruiting

Conditions: Metastatic Colorectal Cancer

Interventions: Drug: Anlotinib
Drug: Irinotecan
Drug: Penpulimab

First Posted Date: 2022-02-08

Last Posted Date: 2024-07-03

Lead Sponsor: Fudan University

Target Recruit Count: 44

Registration Number: NCT05229003

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Fluzoparib and Abiraterone in the preSurgery Treatment of Prostate Cancer: FAST Trial

Phase 2

Active, not recruiting

Conditions: High-risk Prostate Cancer
Neoadjuvant Therapy

Interventions: Drug: Abiraterone acetate
Drug: Fluzoparib
Drug: Prednisone
Drug: Androgen deprivation therapy
Procedure: Radical Prostatectomy

First Posted Date: 2022-02-04

Last Posted Date: 2023-12-08

Lead Sponsor: Fudan University

Target Recruit Count: 34

Registration Number: NCT05223582

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

DDP ip Combined With AG in PDAC With Peritoneal Metastasis

Phase 2

Completed

Conditions: Pancreatic Neoplasm

Interventions: Drug: intraperitoneal (IP) Cisplatin combined with intravenous gemcitabine + nab-paclitaxel

First Posted Date: 2022-02-03

Last Posted Date: 2025-05-22

Lead Sponsor: Fudan University

Target Recruit Count: 91

Registration Number: NCT05222204

Locations: 🇨🇳
Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center; Pancreatic Cancer Institute, Fudan University, Shanghai, Shanghai, China
🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Prognostic Value of Sarcopenia and Nutritional Status in Early-stage Non-small Cell Lung Cancer

Not yet recruiting

Conditions: Sarcopenia
Non Small Cell Lung Cancer
Malnutrition

Interventions: Device: Inbody 570
Device: JAMAR Dynamometer
Radiation: CT scan

First Posted Date: 2022-01-28

Last Posted Date: 2022-01-28

Lead Sponsor: Fudan University

Target Recruit Count: 132

Registration Number: NCT05212285

Locations: 🇨🇳
Huadong hospital, Fudan University, Shanghai, Shanghai, China

Enhanced Systemic Combined With Local Treatment for Primary and Metastatic Lesions in Oligo-metastatic Prostate Cancer

Phase 2

Recruiting

Conditions: Prostate Cancer

Interventions: Drug: Leuprolide acetate
Drug: Goserelin acetate
Drug: Triptorelin acetate
Drug: Degarelix acetate
Drug: Abiraterone acetate
Drug: Apalutamide
Drug: Enzalutamide
Procedure: Local treatment for primary lesion
Radiation: Radiotherapy for primary lesion
Radiation: Radiotherapy for metastatic lesion

First Posted Date: 2022-01-28

Last Posted Date: 2022-03-16

Lead Sponsor: Fudan University

Target Recruit Count: 160

Registration Number: NCT05212857

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Immune Therapy in HR-positive/HER2-negative Metastatic Breast Cancer(ENIGMA)-BCTOP-L-M02

Phase 2

Recruiting

Conditions: Breast Cancer
Metastatic Cancer

Interventions: Drug: Nab paclitaxel
Drug: SHR-1316
Drug: SHR6390
Drug: SERD
Drug: AI

First Posted Date: 2022-01-25

Last Posted Date: 2024-02-08

Lead Sponsor: Fudan University

Target Recruit Count: 338

Registration Number: NCT05205200

Locations: 🇨🇳
Fudan University Shanghai cancer center, Shanghai, China

Neoadjuvant FOLFOXIRI Versus CapeOX Chemotherapy for Local Advanced Rectal Cancer

Phase 3

Recruiting

Conditions: Rectal Cancer

Interventions: Drug: FOLFOXIRI
Drug: CapeOX

First Posted Date: 2022-01-21

Last Posted Date: 2022-03-04

Lead Sponsor: Fudan University

Target Recruit Count: 300

Registration Number: NCT05201430

Locations: 🇨🇳
Department of Colorectal Surgery Fudan University Shanghai Caner Center, Shanghai, Shanghai, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy